Clinical Trial

A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study acronym: XH-S003-II-101
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 18, 2025 (before its estimated August 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, single-blind Phase II trial to evaluate the efficacy and safety of XH-S003 capsules in PNH patients. About 24 PNH patients will be enrolled and randomized to three dose levels and take XH-S003 capsules orally
Trial Details
NCT Number NCT06978699
Lead Sponsor S-INFINITY Pharmaceuticals Co., Ltd
Conditions PNH - Paroxysmal Nocturnal Hemoglobinuria
Enrollment 24 participants
Start Date 2025-04-30
Primary Completion 2025-08-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-18